Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials

Abstract: Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT). DNA methylation profiling can subdivide early-stage patients into naive B-cell–like CLL (n-CLL...

Full description

Bibliographic Details
Published in:Blood Advances
Main Authors: Tomasz K. Wojdacz, Harindra E. Amarasinghe, Latha Kadalayil, Alice Beattie, Jade Forster, Stuart J. Blakemore, Helen Parker, Dean Bryant, Marta Larrayoz, Ruth Clifford, Pauline Robbe, Zadie A. Davis, Monica Else, Dena R. Howard, Basile Stamatopoulos, Andrew J. Steele, Richard Rosenquist, Andrew Collins, Andrew R. Pettitt, Peter Hillmen, Christoph Plass, Anna Schuh, Daniel Catovsky, David G. Oscier, Matthew J.J. Rose-Zerilli, Christopher C. Oakes, Jonathan C. Strefford
Format: Article in Journal/Newspaper
Language:English
Published: Elsevier 2019
Subjects:
Specialties of internal medicine
RC581-951
Arctic
Online Access:https://doi.org/10.1182/bloodadvances.2019000237
https://doaj.org/article/cd01b8a978aa4041a72a417cc4cb4fcc
Description
Summary:Abstract: Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT). DNA methylation profiling can subdivide early-stage patients into naive B-cell–like CLL (n-CLL), memory B-cell–like CLL (m-CLL), and intermediate CLL (i-CLL), with differing times to first treatment and overall survival. However, whether DNA methylation can identify patients destined to respond favorably to CIT has not been ascertained. We classified treatment-naive patients (n = 605) from 3 UK chemo and CIT clinical trials into the 3 epigenetic subgroups, using pyrosequencing and microarray analysis, and performed expansive survival analysis. The n-CLL, i-CLL, and m-CLL signatures were found in 80% (n = 245/305), 17% (53/305), and 2% (7/305) of IGHV-unmutated (IGHV-U) cases, respectively, and in 9%, (19/216), 50% (108/216), and 41% (89/216) of IGHV-M cases, respectively. Multivariate Cox proportional analysis identified m-CLL as an independent prognostic factor for overall survival (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.24-0.87; P = .018) in CLL4, and for progression-free survival (HR, 0.25; 95% CI, 0.10-0.57; P = .002) in ARCTIC and ADMIRE patients. The analysis of epigenetic subgroups in patients entered into 3 first-line UK CLL trials identifies m-CLL as an independent marker of prolonged survival and may aid in the identification of patients destined to demonstrate prolonged survival after CIT.

Similar Items